Single-cell epigenetic profiling reveals an interferon response-high program associated with BAP1 deficiency in kidney cancer
Authors:
- Sabrina Y. CampSCSabrina Y. Camp
- Meng Xiao HeMHMeng Xiao He
- Michael S. CuocoMCMichael S. Cuoco
- Eddy SaadESEddy Saad
- Erica PimentaEPErica Pimenta
- Kevin MeliKMKevin Meli
- Ziad BakounyZBZiad Bakouny
- Chris LabakiCLChris Labaki
- Breanna M. TitchenBTBreanna M. Titchen
- Jack HorstJHJack Horst
- Rachel TrowbridgeRTRachel Trowbridge
Preprint
Abstract
Renal cell carcinoma (RCC) is characterized by recurrent somatic mutations in epigenetic regulators, which stratify patients into clinically significant subgroups with distinct prognoses and treatment responses. However, the cell type-specific epigenetic landscape of RCC—broadly and in the context of these mutations—is incompletely understood. To investigate these open questions, we integrated single nucleus ATAC sequencing data from RCC tumors across four independent cohorts. In clear cell RCC tumors, we identified four shared malignant epigenetic programs related to angiogenesis, proximal tubule-like features, interferon (IFN) signaling, and one that lacked distinct genomic regions with increased accessibility. Among the mutated epigenetic regulators, BAP1 mutation exhibited the most significant impact on chromatin accessibility in tumor cells, and the associated epigenetic changes were linked to IFN response. We identify multiple potential sources of elevated IFN signaling in these lesions, such as increased immune infiltration and increased accessibility and expression of an IFN-associated ERV, ERV3-16A3_LTR. We find that the expression of ERV3-16A3_LTR may itself be a negative prognostic biomarker in ccRCC. Our findings highlight the convergence of malignant epigenetic programs across ccRCC tumors and suggest that BAP1 loss, potentially through ERV3-16A3_LTR dysregulation, is associated with an IFN response-high epigenetic program.Keywords
This publication has 66 references indexed in Scilit:
- Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinomaCancer Cell, 2021
- Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis BlockadeCancer Cell, 2020
- Clinical Validation of PBRM1 Alterations as a Marker of Immune Checkpoint Inhibitor Response in Renal Cell CarcinomaJAMA Oncology, 2019
- Tracking Cancer Evolution Reveals Constrained Routes to Metastases: TRACERx RenalCell, 2018
- Programmed cell death ligand 1 and tumor‐infiltrating lymphocyte status in patients with renal cell carcinoma and sarcomatoid dedifferentiationCancer, 2017
- Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous RetrovirusesCell, 2015
- DNA-Demethylating Agents Target Colorectal Cancer Cells by Inducing Viral Mimicry by Endogenous TranscriptsCell, 2015
- Oncotator: Cancer Variant Annotation ToolHuman Mutation, 2015
- Clinical and pathological impact of VHL, PBRM1, BAP1, SETD2, KDM6A, and JARID1c in clear cell renal cell carcinomaGenes, Chromosomes and Cancer, 2013
- Evolution and Impact of Subclonal Mutations in Chronic Lymphocytic LeukemiaCell, 2013